Related Experiment Video
Updated: Jan 8, 2026

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
Published on: June 4, 2020
Hemorrhagic Transformation after Ischemic Stroke in a Case of Essential Thrombocythemia with Hyperfibrinolysis on
Daisuke Kudo1, Kotaro Noda1, Motohiro Suzuki1
1Department of Neurology and Neurological Science, Institute of Science Tokyo Hospital, Japan.
Essential thrombocythemia (ET) is a myeloproliferative neoplasm that is characterized by thrombocytosis. Because it is characterized by thromboembolic and hemorrhagic events, balancing the coagulation status is essential. Thromboelastography (TEG) is a point-of-care viscoelastic test that evaluates whole-blood coagulation dynamics. We herein describe the case of a patient with ischemic stroke accompanied by ET who underwent TEG. The lysis index after 30 min (LY30) was elevated when hemorrhagic transformation occurred. After augmentation with cytoreductive therapy, the platelet count and LY30 levels rapidly normalized. Our findings indicate that TEG may be therefore useful for monitoring the complicated coagulation status of ET patients.
Essential thrombocythemia (ET) is a myeloproliferative neoplasm that is characterized by thrombocytosis. Because it is characterized by thromboembolic and hemorrhagic events, balancing the coagulation status is essential. Thromboelastography (TEG) is a point-of-care viscoelastic test that evaluates whole-blood coagulation dynamics. We herein describe the case of a patient with ischemic stroke accompanied by ET who underwent TEG. The lysis index after 30 min (LY30) was elevated when hemorrhagic transformation occurred. After augmentation with cytoreductive therapy, the platelet count and LY30 levels rapidly normalized. Our findings indicate that TEG may be therefore useful for monitoring the complicated coagulation status of ET patients.
Related Concept Videos
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Clot Retraction and Fibrinolysis
Venous Thrombosis III: Interprofessional Care
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...

